Mission Bio & Integrated DNA Technologies

To overcome the limitations of bulk analysis in genome editing in applications like therapeutics, which can mask critical off-target events that compromise safety, a workflow that utilizes single-cell insights is required. Here, you will learn how Integrated DNA Technologies' rhAmpSeq™ and UNCOVERseq technology with Mission Bio’s Tapestri® single-cell DNA sequencing platform create a comprehensive, high-sensitivity workflow for the detection of on- and off-target editing.

Join **Nechama Kalter** from Bar-Ilan University as she walks through her latest work that utilizes this workflow to assess the fidelity, safety, and functional consequences of CRISPR-based genome editing. 

**Speakers**

**Nechama Kalter**, Ph.D. student, Ayal Hendel Lab, Bar-Ilan University

**Adam Chernick**, Sr. Commercial Product Manager, Integrated DNA Technologies

**Michael Molnar**, Sr. Marketing manager, Mission Bio

By registering, you agree to share your information with **Mission Bio** and **Integrated DNA Technologies (IDT)**, who may contact you about this event and related products. You can unsubscribe at any time.


Single-cell profiling of genome-editing alterations and functional outcomes in CRISPR-engineered cells